Literature DB >> 23819796

Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol.

Borje Darpo1, Dilip R Karnad, Fabio Badilini, Jeff Florian, Christine E Garnett, Snehal Kothari, Gopi Krishna Panicker, Nenad Sarapa.   

Abstract

AIM: To study the differences in QTc interval on ECG in response to a single oral dose of rac-sotalol in men and women.
METHODS: Continuous 12-lead ECGs were recorded in 28 men and 11 women on a separate baseline day and following a single oral dose of 160 mg rac-sotalol on the following day. ECGs were extracted at prespecified time points and upsampled to 1000 Hz and analyzed manually in a central ECG laboratory on the superimposed median beat. Concentration-QTc analyses were performed using a linear mixed effects model.
RESULTS: Rac-sotalol produced a significant reduction in heart rate in men and in women. An individual correction method (QTc I) most effectively removed the heart rate dependency of the QTc interval. Mean QTc I was 10 to 15 ms longer in women at all time points on the baseline day. Rac-sotalol significantly prolonged QTc I in both genders. The largest mean change in QTc I (ΔQTc I) was greater in females (68 ms (95% confidence interval (CI) 59, 76 ms) vs. 27 ms (95% CI 22, 32 ms) in males). Peak rac-sotalol plasma concentration was higher in women than in men (mean Cmax 1.8 μg ml(-1) (range 1.1-2.8) vs. 1.4 μg ml(-1) (range 0.9-1.9), P = 0.0009). The slope of the concentration-ΔQTc I relationship was steeper in women (30 ms per μg ml(-1) vs. 23 ms per μg ml(-1) in men; P = 0.0135).
CONCLUSIONS: The study provides evidence for a greater intrinsic sensitivity to rac-sotalol in women than in men for drug-induced delay in cardiac repolarization.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  PK/PD; QT prolongation; QT/QTc; gender; gender difference; rac-sotalol

Mesh:

Substances:

Year:  2014        PMID: 23819796      PMCID: PMC4371537          DOI: 10.1111/bcp.12201

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

Review 1.  Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects.

Authors:  Christine E Garnett; Hao Zhu; Marek Malik; Anthony A Fossa; Joanne Zhang; Fabio Badilini; Jianguo Li; Börje Darpö; Philip Sager; Ignacio Rodriguez
Journal:  Am Heart J       Date:  2012-05-04       Impact factor: 4.749

2.  Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.

Authors:  Jae-Gook Shin; Won-Ku Kang; Ji-Hong Shon; Million Arefayene; Young-Ran Yoon; Kyung-Ah Kim; Doo-Il Kim; Dong-Soo Kim; Kwang-Hyun Cho; Raymond L Woosley; David A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

Review 3.  Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

Authors:  Christine E Garnett; Nhi Beasley; V Atul Bhattaram; Pravin R Jadhav; Rajanikanth Madabushi; Norman Stockbridge; Christoffer W Tornøe; Yaning Wang; Hao Zhu; Jogarao V Gobburu
Journal:  J Clin Pharmacol       Date:  2008-01       Impact factor: 3.126

4.  Automatic extraction of ECG strips from continuous 12-lead holter recordings for QT analysis at prescheduled versus optimized time points.

Authors:  Fabio Badilini; Martino Vaglio; Nenad Sarapa
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

5.  Taking the "idio" out of "idiosyncratic": predicting torsades de pointes.

Authors:  D M Roden
Journal:  Pacing Clin Electrophysiol       Date:  1998-05       Impact factor: 1.976

6.  Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.

Authors:  B Houltz; B Darpö; N Edvardsson; P Blomström; J Brachmann; H J Crijns; S M Jensen; E Svernhage; H Vallin; K Swedberg
Journal:  Pacing Clin Electrophysiol       Date:  1998-05       Impact factor: 1.976

7.  Sex difference in risk of torsade de pointes with d,l-sotalol.

Authors:  M H Lehmann; S Hardy; D Archibald; B quart; D J MacNeil
Journal:  Circulation       Date:  1996-11-15       Impact factor: 29.690

8.  Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.

Authors:  Jeffry A Florian; Christoffer W Tornøe; Richard Brundage; Ameeta Parekh; Christine E Garnett
Journal:  J Clin Pharmacol       Date:  2011-01-12       Impact factor: 3.126

9.  JTc prolongation with d,l-sotalol in women versus men.

Authors:  M H Lehmann; S Hardy; D Archibald; D J MacNeil
Journal:  Am J Cardiol       Date:  1999-02-01       Impact factor: 2.778

10.  Cardiac actions of erythromycin: influence of female sex.

Authors:  M D Drici; B C Knollmann; W X Wang; R L Woosley
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

View more
  18 in total

Review 1.  Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence.

Authors:  Matthew P Rochester; Allison M Kane; Sunny Anne Linnebur; Danielle R Fixen
Journal:  Ther Adv Drug Saf       Date:  2018-05-04

2.  Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation.

Authors:  Ana Carolina Moreira Souza; Andrea Grabe-Guimarães; Jader Dos Santos Cruz; Artur Santos-Miranda; Charlotte Farah; Liliam Teixeira Oliveira; Alexandre Lucas; Franck Aimond; Pierre Sicard; Vanessa Carla Furtado Mosqueira; Sylvain Richard
Journal:  Br J Pharmacol       Date:  2020-08-24       Impact factor: 8.739

3.  Estimation of QT interval prolongation through model-averaging.

Authors:  Peter L Bonate
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-18       Impact factor: 2.745

4.  Hypokalemia in women and methadone therapy are the strongest non-cardiologic factors associated with QT prolongation in an emergency department setting.

Authors:  Keith A Marill; Emily S Miller
Journal:  J Electrocardiol       Date:  2017-02-10       Impact factor: 1.438

5.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

Review 6.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

7.  Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Authors:  Rashmi Mehta; Michelle Green; Bela Patel; Jonathan Wagg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-01-06       Impact factor: 2.745

Review 8.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

9.  Sex-Specific Classification of Drug-Induced Torsade de Pointes Susceptibility Using Cardiac Simulations and Machine Learning.

Authors:  Alex Fogli Iseppe; Haibo Ni; Sicheng Zhu; Xianwei Zhang; Raffaele Coppini; Pei-Chi Yang; Uma Srivatsa; Colleen E Clancy; Andrew G Edwards; Stefano Morotti; Eleonora Grandi
Journal:  Clin Pharmacol Ther       Date:  2021-04-19       Impact factor: 6.903

10.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.